Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Clinical trial NCT02691325 · COMPLETED

Trial details

NCT number: NCT02691325
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pulmonary Disease, Chronic Obstructive

Start date: 2016-03-14
Primary completion: 2016-06-05
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.